Benzinga
Benzinga
Benzinga
jueves, septiembre 24

Axsome Therapeutics Inc

AXSMNASDAQ
Trade with Public
Trade with Public
$193.45
-9.65-4.75%
al cierre: Sep 22, 5:00 PM EST
$193.45
-9.65-4.75%
Premercado: 3:00 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararInforme de acciones

Axsome Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Axsome Therapeutics (AXSM).

Price Target Range — 7 Quarters

Analyst Consensus — 20 Analysts

20Buy
Consensus RatingBuy# Analysts20Avg. Consensus PT$236Upside to Avg. PT+21.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Sep 23, 2026Truist SecuritiesSrikripa DevarakondaPT RaiseBuy$200→$285
Sep 18, 2026Piper SandlerDavid AmsellemMaintainedOverweight$258
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285

Truist Securities analyst Srikripa Devarakonda maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200 to $285.
Benzinga Newsdesk

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

U.S. stocks ended mixed; the Dow had its worst week since March. Benzinga highlights top picks from five accurate analysts, including ON, AXSM and LLY.
Avi Kapoor

PRO
Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target

Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $290 price target.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $316

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $306 to $316.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $251

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $242 to $251.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved